0001193125-22-237990.txt : 20220902 0001193125-22-237990.hdr.sgml : 20220902 20220902171537 ACCESSION NUMBER: 0001193125-22-237990 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220829 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Bankruptcy or Receivership ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20220902 DATE AS OF CHANGE: 20220902 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allena Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001624658 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 452729920 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38268 FILM NUMBER: 221226077 BUSINESS ADDRESS: STREET 1: 142 -F NORTH ROAD, SUITE 150 CITY: SUDBURY STATE: MA ZIP: 01776 BUSINESS PHONE: 617-467-4577 MAIL ADDRESS: STREET 1: 142 -F NORTH ROAD, SUITE 150 CITY: SUDBURY STATE: MA ZIP: 01776 8-K 1 d322264d8k.htm 8-K 8-K
0001624658 false 0001624658 2022-08-29 2022-08-29 0001624658 dei:FormerAddressMember 2022-08-29 2022-08-29

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 2, 2022 (August 29, 2022)

 

 

Allena Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38268   45-2729920

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

142-F North Road, Suite 150

Sudbury, MA 01776

   01776
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (617) 467-4577

One Newton Executive Park, Suite 202, Newton, Massachusetts 02462

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   ALNA   The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 

Item 1.02.

Termination of Material Definitive Agreement

On August 29, 2022, Allena Pharmaceuticals, Inc., (the “Company”) entered into a settlement agreement (the “Settlement Agreement”) with Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P. (collectively, referred to as the “Lenders”), in connection with which the Company agreed to pay the Lenders $1.4 million in full satisfaction of all amounts outstanding under that certain Loan and Security Agreement with the Lenders dated September 29, 2020 (the “Loan Agreement”). The Settlement Agreement included a customary release of claims and a release of all liens arising under the Loan Agreement.

In connection with the Settlement Agreement, the Company agreed to make certain additional payments to the Lenders in the event the Company pays certain other creditors of the Company more than 25% of the amount currently owed to such creditors. In addition, prior to any distribution or payment of any kind being made on account of any of the Company’s equity interests, other than non-cash distributions in connection with any reverse merger, the Company agreed to first pay to the Lenders all amounts that would otherwise be outstanding under the Loan Agreement had the Settlement Agreement not been entered into, including any interest, fees and charges that would otherwise have accrued, after giving effect to any payments previously made.

 

Item 1.03.

Bankruptcy or Receivership.

On September 2, 2022, after considering all strategic alternatives, the Company filed a voluntary petition (the “Voluntary Petition”) for relief under the provisions of Chapter 11 of Title 11 of the United States Code (the “Code”) in the United States Bankruptcy Court for the District of Delaware (the “Court”). The bankruptcy case is being administered under the caption In re Allena Pharmaceuticals, Inc. (Case No. 22-10842).

In connection with this Chapter 11 filing, the Company has appointed Matthew Foster as the Company’s Chief Restructuring Officer, effective as of September 2, 2022, and has engaged Mr. Foster’s firm, Sonoran Capital Advisors, LLC, to provide services to the Company in connection with its Chapter 11 case. The Company intends to continue to operate its business at a reduced level as a “debtor-in-possession” under the jurisdiction of the Court and in accordance with the applicable provisions of the Code and orders of the Court.

In connection with the Chapter 11 filing, the Company has engaged SSG Advisors, LLC in connection with any restructuring transaction or asset sale transaction arising under the Chapter 11 case. Any sale of assets would be subject to review and approval of the Court, compliance with agreed upon and Court-approved bidding procedures allowing for the submission of higher and better offers, and other agreed-upon conditions.

The Company currently expects that the Chapter 11 filing will result in, among other things, the cancellation or extinguishment of all outstanding shares of the Company’s capital stock without any payment or other distribution on account of those shares.

 

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously reported, on August 23, 2022, the Company received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that (i) the Company has not regained compliance with its requirement to maintained a minimum closing bid price of $1.00 per share for the required period (the “Minimum Bid Price Requirement”), and (ii) failure to regain compliance with the Minimum Bid Price Requirement serves as a basis for delisting the Company’s securities from The Nasdaq Capital Market unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”).

On August 30, 2022, the Company requested a hearing before the Panel, which has temporarily stayed the suspension of trading and delisting of the Company’s common stock. However, in light of the Chapter 11 filing the Company is unlikely to pursue the hearing further. Accordingly, the Company expects that the Company’s common stock will soon be suspended and a Form 25-NSE will be filed with the Securities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market, after which time the Company’s securities may trade in the over-the-counter market.

 

Item 5.02.

Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

In connection with the Chapter 11 filing, on September 2, 2022, the Company terminated the employment of substantially all of its employees, including Louis Brenner, President and Chief Executive Officer of the Company and Richard D. Katz, Chief Financial Officer of the Company.

As previously disclosed, in January 2022 the Company entered into retention agreements with each of Dr. Brenner and Dr. Katz as a result of which no additional severance payments will be provided in connection with these separations. In connection with such retention agreements, each executive agreed to provide three months of consulting services to the Company, as requested by the Company, at an hourly rate derived using the executive officer’s current base salary.

In addition, on September 2, 2022 and following approval of the Chapter 11 filing and related actions, Louis Brenner, Gino Santini and Allene Diaz resigned from the Board of Directors (the “Board”) of the Company, effective as of the filing of the Voluntary Petition with the Court. At the time of resignation, Ms. Diaz was Chair of the Compensation Committee and a member of the Nominating and Corporate Governance Committee of the Board and Mr. Santini was a member of the Audit Committee and the Compensation Committee of the Board. The resignations are not the result of any disagreement with the Company regarding the Company’s operations, policies or practices.

* * * * *

Cautionary Information Regarding Trading in the Company’s Securities.

The Company’s securityholders are cautioned that trading in the Company’s securities during the pendency of the Chapter 11 case is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders thereof in the Company’s Chapter 11 case. As noted above, the Company currently expects that the Chapter 11 filing will result in, among other things, the cancellation or extinguishment of all outstanding shares of the Company’s capital stock without any payment or other distribution on account of those shares. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the outcome of the Company’s Chapter 11 filing and the expected delisting of the Company’s equity securities on the Nasdaq Stock Market. Any forward-looking statements in this Current Report on Form 8-K are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Additional risks and uncertainties include, but are not limited to: the Company’s Chapter 11 strategy; risks and uncertainties associated with Chapter 11 proceedings generally; the negative impacts on the Company’s business as a result of filing for and operating under Chapter 11 protection; the time, terms and ability to confirm a Chapter 11 plan of reorganization for the Company; the adequacy of the capital resources of the Company’s businesses and the difficulty in forecasting the liquidity requirements of the operations of its business; the unpredictability of the Company’s financial results while in Chapter 11 proceedings; the Company’s ability to discharge claims in Chapter 11 proceedings; negotiations with the holders of the Company’s indebtedness and its trade creditors and other significant creditors; and risks associated with the Company’s ability to identify and consummate financing and strategic alternatives that yield additional value for shareholders. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this Current Report on Form 8-K is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: September 2, 2022   Allena Pharmaceuticals, Inc.
    By:  

/s/ Richard Katz

      Richard Katz, M.D.
      Chief Financial Officer
 EX-101.SCH 2 alna-20220829.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 3 alna-20220829_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 4 alna-20220829_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Securities Act File Number Securities Act File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Domain] Entity Addresses, Address Type [Domain] Former Address [Member] Former Address [Member] Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] EX-101.PRE 5 alna-20220829_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Aug. 29, 2022
Document And Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Aug. 29, 2022
Entity Registrant Name Allena Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code DE
Securities Act File Number 001-38268
Entity Tax Identification Number 45-2729920
Entity Address, Address Line One 142-F North Road
Entity Address, Address Line Two Suite 150
Entity Address, City or Town Sudbury
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01776
City Area Code 617
Local Phone Number 467-4577
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ALNA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
Entity Central Index Key 0001624658
Amendment Flag false
Former Address [Member]  
Document And Entity Information [Line Items]  
Entity Address, Address Line One One Newton Executive Park
Entity Address, Address Line Two Suite 202
Entity Address, City or Town Newton
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02462
XML 7 d322264d8k_htm.xml IDEA: XBRL DOCUMENT 0001624658 2022-08-29 2022-08-29 0001624658 dei:FormerAddressMember 2022-08-29 2022-08-29 0001624658 false 8-K 2022-08-29 Allena Pharmaceuticals, Inc. DE 001-38268 45-2729920 142-F North Road Suite 150 Sudbury MA 01776 01776 617 467-4577 One Newton Executive Park Suite 202 Newton MA 02462 false false false false Common Stock, par value $0.001 per share ALNA NASDAQ true true EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 2 24 1 false 1 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d322264d8k.htm alna-20220829.xsd alna-20220829_def.xml alna-20220829_lab.xml alna-20220829_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d322264d8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 2, "dts": { "definitionLink": { "local": [ "alna-20220829_def.xml" ] }, "inline": { "local": [ "d322264d8k.htm" ] }, "labelLink": { "local": [ "alna-20220829_lab.xml" ] }, "presentationLink": { "local": [ "alna-20220829_pre.xml" ] }, "schema": { "local": [ "alna-20220829.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 1, "nsprefix": "alna", "nsuri": "http://www.allenapharma.com/20220829", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d322264d8k.htm", "contextRef": "duration_2022-08-29_to_2022-08-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d322264d8k.htm", "contextRef": "duration_2022-08-29_to_2022-08-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 1, "tag": { "alna_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://www.allenapharma.com/20220829", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "alna_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://www.allenapharma.com/20220829", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Entity Addresses, Address Type [Domain]", "terseLabel": "Entity Addresses, Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]", "terseLabel": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number", "terseLabel": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_FormerAddressMember": { "auth_ref": [ "r6", "r7" ], "lang": { "en-us": { "role": { "documentation": "Former address for entity", "label": "Former Address [Member]", "terseLabel": "Former Address [Member]" } } }, "localname": "FormerAddressMember", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.allenapharma.com//20220829/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Form 10-Q", "Number": "249", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r7": { "Name": "Form 8-K", "Number": "249", "Publisher": "SEC", "Section": "308" }, "r8": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r9": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001193125-22-237990-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-237990-xbrl.zip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

/\32)W#=*CL;V*QPN=H,A6FB, M!3T%'!EG0R11W"M\'$1)$DWHFT&D@'3W32>^93H*I,^^:]-_:OO_^*ZSU=[= M:\6+)EI?/5'WP1,5AMV 0=C\ M@0MJ:AY9^BU]G./@_Y1 ;3WB5(K6:GXH:= M1Q,>[M*S&T/W( K\W8KM^?7TZ/+P$[NX/+@\O%A,3ON%R+DX[/]Z?G1Y='C! M#DX_LEI.KSE_,3MJ=C'F:&:"P3T8!O/ '@Z4;Q&,!$&>7E*.U3Y*5HIPM8^>X@ MC7!X&:+MM9"4_3>)>1:)>1(=!RMT?GAZR)CT?!FA,H/\89VGX?-J8"JX:(JSM'Z2C%,CN M[ABZ9BW.K&R\V9HGL37=C:<0QH4B9,*.5K9UQS70L/(SC?"9#)A/- MP+: >JHWZ;ZC=#^&,9A8Y(- ,$\$ 0(G2MBW:_0YYK[O/MNY[%J]* AXK$7/ M_;%<1@H"A==K6S)[;1<0(F'*_..7X\SUC1\P1928K&CV\%HH M4@++7+/>JH9VE.[=1W$$5_:8'0[^S]*M7).8CT1CH 2_PCJ ]$6/7T<@'7=F M6H>VK30M*P@2*TE2CV2(S:P$Q $(+(+E6<6=>4SC9QG[7AK'0GD<=GJE:0,; M%"EPL63#+A+P;_TH#1,U[4?^HWPEUA@P)9*(6$77."TZR4\BX#=88[M_GGQ3F-]N[LUEQ;_&[#MDM\>V>RA M1WQZ( \W-AO=]]V=G6[[#DQ\#KNP_41FX6'8X$F"^#4R$!CM1,E8*/8?B#&T M+RD6NA=PZ3P#<8!59-&8O3/^]U54XC7WJ!]-)E+KKV%+T.0QHZ]_U]TX:IXW M+YKLW>F]B+%.ACGJ=OO%'7!F MW58$":_'E&\!])=MZW)6KEEF8>XN5B"U,N8!$[?"2Q-YC2D]ZKR?JS@\HMYZ',&.G>%B'AIN;[UO;&R^GR.J MNO#Z&COX[##A4:>POH 8P7H2P.B'F>Z><77U"A#B40LQZ ,&>RCA#_;^CR+; M\/YU<,-C"%^=@CWA6G-OG&J1)/H5X,FCMJ7=W=B:DZ3'U,R>)LHWM-J:F:(] M@(_C9EF#@/7]BTW M8/E%=K"X< [J/ 4)V>AN6O%,RB>/\,#16N<]ZW\^9]WU=A,:WBO9^":T=Q': MBX@.ML/$)V"_P(@%?UN)S5D!0QM>S(OK'7)WO-'I.FN>2W;I()V3ZY6C=3?: M33/BNT+L\Z8"3ZD"9TJ@S<;7C>B0,#I=]64XO'_<^I=1A95R"3QK> 6F.7E? M9>WOH#Y^H[LV>/>T"F3&?%.A%U*A(ZU3H=X4Z545:5TT-M:\IU4D.^;=%>DU M4G,%#&E"(*$@B(H7'L!'T^#B(F#)XC#H&RA?OYVY?)DRRQW2&0O66I5'?\43 M'9=XP0!*O^#>F'D!U_IE2GT/Y>#KGLBY5!QU]M4/XEQ,)_!H3;_0P:AO<[-. M[4L()-K">KU7W[HH9& $@*+<.="O\*:]0+N64-C-'O^[\K='PZ M=V;DFV2#$QJ'51_RYM1<$($FP-6Q\#7'4ZY]_H<1+';"U95(5I_P>'Z06]L_ M"GU$_H(-ILRC.@.,> 5F0]#!Z9GDOM0,> S1 TXZ8B,5W21C#"!B3/ASS7PQ ME*%YZX8A70'C2P9 M-C]GU=NEJP=UU&%$,C=^@;ZD4DE3] M,G>A($]HKF"*D]](F!K5(03ZX(D2UU)#/U ,'GJ8Z>6>AZ\N86.\>F M..8OC1[7UW@6/1;%N7D?*;B]S.@WKQN_C@@\JGK\5[O6Q920YPK)!3PV$,!U MP&/!#9_JFF7F.$-N$+Q'JO?=#OUGU]$9WY9R>*T7OW_G+Y&@['069"B7XXVC M1$RLWC;;W6;1N[.5>4/VC(G#98&#R21>"C4!8^4*_*Y:QSZA6(9>LI3/V7D)D+#.SE"O86@SI;]O)ZG:VAT<03D-WV;M_Y3OC4V7W' M2/H)M(#)Y0S/&P6T.,;=,DO]+_(&&1^RP;FK(<=AWW?:6X85L-^!#@$##A,@\"> M#.&>DQ-P 8Q/T+-I%J4)N3;T<2X=S!/02I5PZ'\<@>K@ZAWXSAEI*"Q2@'=9 M^'.7:IA];YEQI($<(C)75QD8*5B5@&#+M/ ^#GMC=9L-SZ@BV?\"N1;0W:4!P**](@ M@ )W$]H4-P1:$2*B>T^*0T('G0UDWKST0$AE$BGM@(MK.P%_AD(1LN[F#^ZA M$1_8"Y#M, FF++JQAY)23!FZL9J@U!FA=3P]#C@+-0'&]1'+R4%JI%*Y1="N MP>,KP()L($SEW8?-#!T< MUV,7/Q2IU%4JBI0 <@1V"X:P%D]I5^_>4"J=&+4M;U-1'TG[;J(T\ W9-P!) M@0V5>CHKPH"*_84R13!Y '%NR8J63I2'.=?J;"B$T2>\CV,D%E VYN!C8%]4 M*OPZXT/HS4;R&H<3PR'PR>UV)J(QPFQS8@WW=5;M"BJU_=%EWC_V:/S^SC#+$,*4@%=S8L MF(#\K"8:Q+Y)<[!.!S^90DZG8PBP]O)70(;HIO$4MZ9W8F8PER^R&:T#*7K ^ M?!%]3AGH[YY,0+ \9Q7 ^0 %RR]+(C4QS0'( 06G49-!#-UI;V]TEZ:+G@\5 M !,*&VD.\Y:]"N8_>!Q':*]]!/[P\(9]CI!?#F?..$:SQOX8Q><<3+Q*O20E M,?Y"+W"!WS(F&\,&3M*T4!/ +5 &)AQQ/()^HFQFPQ"0N6+P>),ZNXC"2,%N M]7F,V\,.?!!8 =U=GS)-404>H>P8@-MI50,K M^+X8 !P"X]^((WP[0>=J7;XKI"#IQ:LP7PCJ[Z"]3GH#99- 1:^VW - MBER4G[I)K,I<'"WP3>/(1)#4K&$ZP_<#2>@)Q12T+E6"<+!Y_\ Y%)C?7CR" M(Y,&WMD0+Z9M$&3 A--X*&?W8H7#4\>$XG;&+AGD7.E M6 "G $+ VM, 8]PZA@'XWH8-6*"%11(>\A70J]MOT -XF$H]SF(F&*@8)%#Y M;'>^)1Q_ M&@%!PJ(_D!IZ!4FQSUP&J2+O>V'?4>*L;WVRSXYM2RH>0O,+6VG9950 &9*> MNU8O'Q R5O1:V:',B:[62>%\ \%=?(>Z!%6I/O#.VSK@DS M!4J,.!6(9\TZ B>%.19ET@J4E@*P95ISAJA]DDZ8%T3D>L#.8]['R,7W>$PH M/YV1&7H[H.\*=<6EG]@!/\) 9S30>3Y]GCU%'[ FW9*&NKM:"VA!)!XS*\)F M1''=YKI1_L XI5K2N);C0F?"M^B 1V;'_ @WV,.Q="^YWNRR-V9XT+D[9KL MI^@&$W:4<0_0GF7=YOQS*0K1N&GR"O<(@Q8L_YH5N$4- >& RP101= 4BPA%*##G0$GP=N^90#IRSWW=XB[6XV3B\.771! P[H_5 8IY"#SJ06 MQ\Y*UOG%;V5C=-C/]H6/S+GJ7'08BB_.SQKOLP&1X',3OVX)-W@^%'TPBA^93=J 4 M:JU)LU(=1L7JIT1D3,,N*1,Y/ M96>M*G(B0#<&GZAG!CM3L7&V%=4CJU92=T? W1X7*NLV'9F,X1M&/\Y "H6I M?U@'1=?5F'.X/IS$.4+@:AMD*8AVE(+"1@?)!JAS9F[]7*LZDVL8!8 M5&#*!G;P)=+3>?EVH9+2ON?71\PEB.9@E7'[ 2FR255A[JNLD3_*$ -&#!,E M=: \/E89^)\H46!K\;">BZ<^1JB%)6-;Q"STN!A E39F-O%=O$/#?)HORQ3L M&250V8%!=(1,Z&<.D$1N6'>BK5(0]3>R9!3(CN.XA+H@6!06Z$W,S]?9 MIJ>1.?)CN=BWUQ,+]B-B$W,B)1_!=C+,P?99JMYQ]H8TM#S' 9C(9(:.)606 M)S%)^,+:\>2%,&P1 #Y_G"0/&T:<0'0ESC.)?",Y,;VE+\B]Q@H% MRIM/2#VQ;E2]QO$_S/YWR=3;S_#&8Q60*M?#^ISR=RB_1V'V&[P0[CH6VW<, M'%*>Y78>(339R@O7G@0[7"[&]M,QK)D.3BC,C-+*"!%@3+5\'87HP+>)=*RA M8EP5>M,*@^6*DIA\QG 4PK(HS"0]5?DJW09$9 W_C6(-QJ* +S"OG MG2\#4-H'S?$ !BVCKK]K1GMQ&)_2B1@@&5-%3@2-!8..L:V9B-M"E#M,*1J0 MX35@ X-R[ _>Y#+P5H1[<6MX"D)?,(.?(W4#?S:.H^@*/].1![-;+V7VL/AO MD9[])3,\:WK?*\/<&4BL?4,0J!T.&MH%!G:!.EN@!4TZP8($CL^J*W),IDR[FG3&S3[-SZ-00XOO8&V2"C[), M=RD,,"NU& O6: T,'?:T)V%5J83+[2VR!$[12U&C-+3G0(D%YO OU7_!JNF" MKTN&.+['JFEV'%)@PF/MT!!(^641.=E30X2"L&I"-Q]\BER8NHKAL,4.! MX7F N(A8>R@8_!Y:>HLR2;XHCNNM$AU[=&NZNW &KG7D20I3R+@7.E/=6OB4 MA1]!7**0%;LT92A&!B' >CFZRZC:">?G3\I!LA5IQ Q4V39(-ROCEXE(3+2[ MF\4>=,X6'HK] ]X:&*52(U U_\TJCR#5LS8W >-X3E( M<@XW^R7I18KFEFFSR]@$94@"D*)SNCB= !22%54"":KI(]V%0E,V? [\77[' M36#H3,,8CQ^#:MC%+R K?\W+"3!%LXXL]''H;0'),L2#1,(W0H.G@% E*<.=']_.#T-@#$:E13RI[9[OFN#; M"/R,>*]8G_W-=:/PE R9H!5PG+16N/I I+$L4RD"OYC[,6]MH[P1YK+K;Z+5 M!$E%AJ;9^0^SJ 6J6CP$(K%\A'B$F4C;S!2R,<$*C'7*Y[ F]MG0ZMSP N#^2TJ_C@AV]KXNIM-N M_))=*&H5_ \S&C-UI7^EH9BMXX%INA$!G8?+=\-&+7/YZ?GCQW!G4 MXH\\%XXZE%S:BK??Z[9CZ>UG/PVFQH;Y1IS,T12:EMYQM;'IKI-:6EJLOIZJ M:VKR032[3@D=O]?"/3(8./T][ST7R_*ZE6 M7&-P3[?5TJVLM(V%W!>XCFHUMY]I$[^M88N[4F. P TPP !$ M ( ! &%L;F$M,C R,C X,CDN>'-D4$L! A0#% @ M\(DB56#&:C"K!0 138 !4 ( !O0, &%L;F$M,C R,C X M,CE?9&5F+GAM;%!+ 0(4 Q0 ( /")(E6G<>3^N0< $E9 5 M " 9L) !A;&YA+3(P,C(P.#(Y7VQA8BYX;6Q02P$"% ,4 " #P MB2)5:3D$LE@% "A.0 %0 @ &'$0 86QN82TR,#(R,#@R M.5]P&UL4$L! A0#% @ \(DB50 ADQ2]&@ 2)4 X M ( !$A< &0S,C(R-C1D.&LN:'1M4$L%!@ % 4 1 $ /LQ ! $! end